---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009944"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:49:47.068023+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProMIS reports Q1 2023 results, FDA clears IND for Alzheimer's candidate PMN310

## Summary
- FDA cleared IND for lead therapeutic candidate PMN310 for Alzheimer's disease; phase 1 enabling activities underway.
- Cash and cash equivalents of $3.3M as of March 31, 2023, down from $5.9M at December 31, 2022.
- Net loss of $5.0M for Q1 2023 compared to $2.1M in Q1 2022, driven by increased R&D spending on PMN310.
- R&D expenses rose to $3.5M from $1.9M YoY, primarily for drug product manufacturing and IND filing costs.
- Preclinical data presented at AD/PD and AAN conferences showing PMN310 selectivity and memory protection in AD models.

## SEC filing metadata
- accession: 0001558370-23-009944
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/0001558370-23-009944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/pmn-20230515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009944
- JSON: https://secwatch.observer/filing/0001558370-23-009944.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009944.txt

## Key facts
- Earnings Releases
  ProMIS Neurosciences Inc. reported the quarter ended March 31, 2023 results: net income $5.0 million.
  - Period: the quarter ended March 31, 2023
  - Net income: $5.0 million
  - Result: reported results
  source text: Net loss was $5.0 million for the quarter ended March 31, 2023, compared to $2.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/0001558370-23-009944-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.